Sysmex (OTCMKTS:SSMXY) Issues FY 2025 Earnings Guidance

Key Points

• Sysmex has issued FY 2025 earnings guidance with an EPS forecast of 0.632 and revenue guidance of $3.7 billion.
• The company's stock has fallen 9.8% to $13.76 following the earnings update, with a current market capitalization of $8.66 billion.
• In its last quarterly earnings report, Sysmex missed analysts' expectations with an EPS of $0.12, falling short of the anticipated $0.16.

Sysmex (OTCMKTS:SSMXY - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.632-0.632 for the period. The company issued revenue guidance of $3.7 billion-$3.7 billion.

Sysmex Stock Down 9.8%

Sysmex stock traded down $1.50 during midday trading on Thursday, reaching $13.76. The stock had a trading volume of 70,929 shares, compared to its average volume of 83,189. Sysmex has a 1-year low of $13.73 and a 1-year high of $22.00. The stock has a market capitalization of $8.66 billion, a P/E ratio of 24.57 and a beta of 1.15. The firm's fifty day simple moving average is $16.79 and its 200-day simple moving average is $17.84. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.30 and a current ratio of 2.97.

Sysmex (OTCMKTS:SSMXY - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.16 by ($0.04). The business had revenue of $958.89 million for the quarter, compared to analyst estimates of $991.22 million. Sysmex had a return on equity of 11.81% and a net margin of 10.56%. As a group, analysts expect that Sysmex will post 0.57 EPS for the current fiscal year.

Sysmex Company Profile

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.